Globus Medical, Inc. (NYSE:GMED) Shares Sold by Vaughan Nelson Investment Management L.P.

Vaughan Nelson Investment Management L.P. decreased its position in shares of Globus Medical, Inc. (NYSE:GMED - Free Report) by 6.8% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,059,472 shares of the medical device company's stock after selling 77,225 shares during the quarter. Vaughan Nelson Investment Management L.P. owned 0.78% of Globus Medical worth $75,795,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. Sheaff Brock Investment Advisors LLC raised its position in Globus Medical by 0.8% during the third quarter. Sheaff Brock Investment Advisors LLC now owns 39,024 shares of the medical device company's stock valued at $2,792,000 after acquiring an additional 321 shares in the last quarter. KBC Group NV increased its holdings in shares of Globus Medical by 0.5% during the 3rd quarter. KBC Group NV now owns 45,505 shares of the medical device company's stock valued at $3,255,000 after purchasing an additional 237 shares in the last quarter. Geneva Capital Management LLC lifted its stake in shares of Globus Medical by 1.1% in the 3rd quarter. Geneva Capital Management LLC now owns 1,598,130 shares of the medical device company's stock valued at $114,330,000 after purchasing an additional 18,117 shares during the period. Lisanti Capital Growth LLC boosted its position in Globus Medical by 68.4% during the third quarter. Lisanti Capital Growth LLC now owns 24,915 shares of the medical device company's stock worth $1,782,000 after purchasing an additional 10,120 shares in the last quarter. Finally, River Global Investors LLP lifted its holdings in Globus Medical by 0.7% during the third quarter. River Global Investors LLP now owns 47,067 shares of the medical device company's stock valued at $3,366,000 after purchasing an additional 331 shares in the last quarter. 95.16% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

GMED has been the topic of a number of recent research reports. Morgan Stanley boosted their price target on shares of Globus Medical from $74.00 to $83.00 and gave the stock an "equal weight" rating in a research report on Monday, November 11th. Stifel Nicolaus boosted their target price on shares of Globus Medical from $80.00 to $92.00 and gave the company a "buy" rating in a report on Wednesday, November 6th. Piper Sandler increased their price target on Globus Medical from $80.00 to $100.00 and gave the stock an "overweight" rating in a report on Wednesday, November 6th. Roth Mkm reissued a "buy" rating and issued a $100.00 target price on shares of Globus Medical in a research report on Wednesday, November 6th. Finally, Bank of America raised their target price on Globus Medical from $55.00 to $80.00 and gave the company an "underperform" rating in a report on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $88.18.

Insider Activity at Globus Medical

In other news, Director Ann D. Rhoads sold 15,000 shares of Globus Medical stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $70.36, for a total value of $1,055,400.00. Following the sale, the director now owns 42,884 shares of the company's stock, valued at $3,017,318.24. The trade was a 25.91 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Kelly Huller sold 5,000 shares of the business's stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $81.01, for a total transaction of $405,050.00. The disclosure for this sale can be found here. Insiders sold a total of 110,000 shares of company stock valued at $8,512,850 in the last three months. 18.54% of the stock is currently owned by company insiders.

Globus Medical Stock Performance

Shares of GMED remained flat at $81.10 during midday trading on Friday. 982,026 shares of the stock were exchanged, compared to its average volume of 1,034,411. Globus Medical, Inc. has a fifty-two week low of $44.02 and a fifty-two week high of $84.87. The firm has a market capitalization of $10.98 billion, a P/E ratio of 121.04, a price-to-earnings-growth ratio of 1.94 and a beta of 1.17. The business has a fifty day moving average price of $73.36 and a two-hundred day moving average price of $69.68.

Globus Medical (NYSE:GMED - Get Free Report) last posted its earnings results on Tuesday, November 5th. The medical device company reported $0.83 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.18. The firm had revenue of $625.71 million during the quarter, compared to analysts' expectations of $604.69 million. Globus Medical had a return on equity of 9.98% and a net margin of 3.69%. The firm's revenue was up 63.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.57 earnings per share. Research analysts expect that Globus Medical, Inc. will post 2.98 earnings per share for the current year.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.